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Abstract
The TGFb and Ras-MAPK pathways play critical roles in cell development and cell cycle regulation, as well as in
tumor formation and metastasis. In the absence of cellular transformation, these pathways operate in opposition to
one another, where TGFb maintains an undifferentiated cell state and suppresses proliferation, while Ras-MAPK
pathways promote proliferation, survival and differentiation. However, in colorectal and pancreatic cancers, the
opposing pathways’ mechanisms are simultaneously activated in order to promote cancer progression and
metastasis. Here, we highlight the roles of the TGFb and Ras-MAPK pathways in normal and malignant states, and
provide an explanation for how the concomitant activation of these pathways drives tumor biology. Finally, we
survey potential therapeutic targets in these pathways.
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Introduction
A cell must acquire several key characteristics in order
to become cancerous: proliferation without limit in the
absence of extracellular signals, resistance to apoptosis,
evasion of anti-growth signals and immune destruction,
as well as increased cellular motility [1,2]. The TGFb
and Ras-MAPK pathways have each been implicated in
all of the cellular processes that a cancer cell must
exploit on the path to malignancy. However, it is
becoming increasingly clear that these pathways interact,
such that the resulting signal crosstalk contributes lar-
gely to the acquisition of many of the key characteristics
of a cancer cell.
The TGFb signaling pathway regulates differentia-
tion, migration, and death during normal development.
Mutations to the TGFb signaling pathway are com-
monly seen in many genetic diseases and cancers [3-5].
For example, early lesions in colorectal and pancreatic
cancers frequently include mutations of the cell surface
TGFb receptors or Smad transcription factors. How-
ever, the role of the TGFb ligand in cancer progression
has been somewhat puzzling and paradoxical due to its
multiple, often opposing, effects on cell growth. This
TGFb paradox is best exemplified by the fact that
TGFb has been shown to act not only as a tumor sup-
pressor, but also as a promoter of tumor growth and
metastasis [6,7].
Ras-MAPK signaling has been linked to fundamental
cell processes such as differentiation, migration and pro-
liferation [8,9]. The GTPase Ras and the Ras-MAPK cell
surface receptors that initiate the intracellular signaling
pathway (EGFR, FGFR, etc.) are often mutated in color-
ectal and pancreatic cancer, and these mutations lead to
a constitutively active Ras-MAPK pathway [10]. Once
commandeered, MAPK transcription factor substrates
promote unchecked cellular proliferation, leading to
tumor initiation. This review will examine the parallels
between and intersections of these two pathways, with
emphasis placed on their relevance in colorectal and
pancreatic cancers. We will explore how the interactions
between these pathways contribute to the physiological
changes displayed by cancer cells, and how these inter-
actions are modulated throughout tumor progression
and metastasis.
The canonical Ras-MAPK pathway
The Ras-MAPK (Mitogen Activated Protein Kinase)
pathway begins with growth factor binding to trans-
membrane Receptor Tyrosine Kinases (RTKs) (Figure
1). Growth factor binding initiates homodimerization
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of the RTKs [10,11]. Growth factor receptor-bound
protein 2 (Grb2) is then recruited to the cytosolic por-
tion of the RTKs via a Src homology 2 (SH2) domain
which binds to phosphotyrosines. Grb2 then recruits a
guanine exchange factor, Son of Sevenless (SOS), via
an SH3 domain and the GTPase Ras [10,11]. Ras, a
protein that was originally identified as the transform-
ing component in oncogenic viruses, is then post-
translationally modified with an isoprenyl group that
localizes it to the plasma membrane [2,12]. The
GTPase activity of Ras is enhanced by the GTPase
Activating Protein (GAP). Ras recruits and activates
the MAPK kinase kinase (MAPKKK) Raf which initi-
ates a phosphorylation cascade from Raf to MEK
(MAPKK) which finally phosphorylates ERK (MAPK,
Extracellar Regulated Kinase). Phosphorylated
ERK then translocates to the nucleus where it
phosphorylates transcription factors important for pro-
liferation and differentiation [10,11].
The regulation of the activity and the specificity of
MAPKs is critical for proper function and accurate
transduction of extracellular signals. ERK is deactivated
by MAPK phosphatases, resulting in a pathway that can
terminate signaling in the absence of upstream stimuli
[13]. The binding sites on ERK, auxiliary to the sub-
strate recognition motif in the active site of ERK, confer
the specificity for substrates [14]. Recent studies indicate
that scaffolding proteins may play an important role in
the timing and the amplitude of Ras-MAPK by regulat-
ing the location of MAPK components [15]. The scaf-
fold either sequesters them to the cytosol and delays a
response or facilitates a faster phopsphorylation cascade
through the spatial concentration of the kinases (Figure
1), as has been shown for the scaffolding protein KSR
(Kinase Supressor of Ras) [15,16].
Figure 1 Schematic of the Ras-MAPK and TGFb pathways. The left-hand side of the schematic depicts the Ras-MAPK pathway while the
right-hand side of the schematic shows the Smad-dependent TGFb signaling pathway. The details of both pathways are elaborated in the text.
Both pathways begin with extracellular factor binding transmembrane cell surface receptors and end with transcriptional changes. Differences in
the Ras-MAPK and TGFb pathways are evident in the method by which stimulus signals are relayed to the nucleus. The Ras-MAPK pathway
utilizes a phosphorylation cascade that results in signal amplification and a nonlinear switch-like response to stimulus. The TGFb pathway is
depicted here as a linear response to stimulus due to the direct interaction of transcription factor Smads with transmembrane receptors TGFbRI
and TGFbRII. Box 1, 2 and 3 indicates points of integration that are detailed in the text.
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TGF-b signals through two receptor types, the TGF-b
type I and type II receptors (TbRI and TbRII, respec-
tively) [17]. Both receptors are Ser/Thr kinases. While
t h et y p eI Ir e c e p t o ri sc o n s t i t u t i v e l ya c t i v e ,t h et y p eI
receptor is inactive in the absence of ligand[18]. TGF-b
can bind the type II receptor independent of the type I
receptor [19]. Upon binding of the ligand, TGF-b
induces oligomeric receptor complex formation which
enables the type II receptor to phosphorylate the type I
receptor in the GS domain and consequently cause a
conformational change and release of inhibitory mole-
cules such as FKBP12[18,20]. Activated TbRI recruits
and phosphorylates Smad2 and Smad3 (R-Smads), a
process that is aided by SARA (Smad Anchor for Recep-
tor Activation)[21,22]. Phosphorylation of the R-Smads
causes a conformational change such that the R-Smad is
released from SARA [21]. Phosphorylated R-Smad binds
Smad4 forming a R-Smad/Smad4 complex, as well as
forming homo-oligomeric complexes, which translocate
to the nucleus and directly interact with DNA, resulting
in the recruitment of coactivators or chromatin remo-
deling components [23]. The recruitment of coactiva-
tors, corepressors and chromatin remodeling
components determines the ultimate Smad dependent
cellular response to the ligand stimulation [23]. TGF-ß
regulates the transcript levels of approximately 100-300
genes in various cell types (Figure 1) [1-3].
The Non-canonical TGFb pathway
Activation of Smads by TGF-ß is invariant in most cell
types and therefore this pathway is known as the cano-
nical TGF-ß pathway. Beside activation of Smads, TGF-
ß also modulates the activity of several other signaling
pathways in a ligand and receptor dependent manner (e.
g. MAP kinase (MAPK) pathways, Rho-like GTPase sig-
naling pathways, and phosphatidylinositol-3-kinase
(PI3K)/AKT pathways [24-26]). Unlike the canonical
pathway, modulation of these pathways by TGF-ß is
often cell type specific and context dependent [27].
They are collectively referred to as non-Smad or nonca-
nonical TGF-ß signaling pathways. Although canonical
TGF-ß signaling through Smads dominated the field of
TGF-ß research over the last decade, there has been
increasing attention paid to the noncanonical TGF-ß
signaling, particularly in the context of cell migration
and epithelial-mesenchymal transition (EMT). In mam-
malian cells, all three MAPKs are activated by TGF-ß
(Figure 1) (Each MAPK has different isoforms and, for
simplicity, they are generically referred as Erk, JNK and
p38). However, the kinetics of these activations vary
with cell types and culture conditions [24-26,28,29]. The
upstream signal transducers to MAPKs are likely small
GTPases (Ras, Rac, RhoA and Cdc42) [24-26,29]. Their
activities are frequently regulated by TGF-ß through
diverse mechanisms. Here, we will focus on the Ras-
MAPK pathways. For detailed discussions on the various
noncanonical or non-Smad TGF-ß pathways, please
refer to several excellent reviews on this topic
[24-26,30].
I th a sb e e nk n o w nf o rs o m et i m et h a tT G F - ßr a p i d l y
activates Erk MAP kinases through Ras, but the magni-
tude of the resulting activation of Erk1/2 is much lower
compared the activation by RTKs [28]. One mechanism
that has been identified involves phosphorylation of
ShcA by the TGFb receptor complex on the tyrosine
residues of ShcA. Similar to the RTK signaling, ShcA
phoshotyrosines recruit the Grb2/SOS/Ras complex
which subsequently trigger the activation of the Ras-
MAPK pathway (Box 1,F i g u r e1 )[ 3 1 ] .T h eb i o l o g i c a l
significance of intrinsic activation of Ras-MAPK by
TGFb in normal cellular process is still poorly under-
stood. Gene expression profiling studies implicate that
TGF-b-stimulated Erk activation is involved in the mod-
ulating of a subset of genes that figure prominently in
cell motility and cell-matrix interaction [32]. Some of
the genes are often associated with epithelial to
mesenchymal transition (EMT), an indispensable
mechanism for producing mesenchymal cells, tissues
and organs during normal development [33-35]. Thus,
the intrinsic, relatively low, activation of Ras-MAPK is
likely crucial for specific induction of genes regulating
EMT and cellular motility.
Signaling Crosstalk Between the Ras-MAPK and TGFb
pathways
The integration of Ras-MAPK and TGFb pathways can
occur via balanced activation of both canonical and
noncanonical TGFb pathways by TGFb alone, through
simultaneous stimulation of TGFb and ligands of other
signaling pathways that modulate the activity of Ras-
MAPK, or through crosstalk via interactions between
the intracellular effector proteins distinct to each of the
two pathways. In the two lattermost mechanisms, there
are two common points of integration of the Ras-MAPK
and TGFb pathways: 1) phosphorylation of coactivators
of R-Smads by Erks, 2) phosphorylation of Smad2/3 by
Erks in the linker region. Most of the TGFb signaling
responses are cell context dependent [27]. The cell type
specific responses are in part due to Smad interaction
with cell type specific transcription factors [23]. For
example, activated Smad3 binds its cognate sites with
Oct4 in embryonic stem cells (ESCs), MyoD in myo-
tubes and PU.1 in pro-B cells [23]. The association
between activated Smad2/3 and transcriptional cofactors
can be regulated by the Ras-MAPK pathway. For exam-
ple, Ras-MAPK activity has been shown to regulate the
interaction of p53 and Smad2/3. In this mechanism,
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phorylation at its N-terminus (Ser6 and Ser9) by CK1
Î/δ [36]. Such phosphorylation of p53 enables its inter-
action with activated Smad2/3 to regulate target genes
that are important for TGFb cytostatic program [36].
Similarly, Src-activated Epidermal Growth Factor Recep-
tor (EGFR) signals through Ras-MAPK to engender
phosphorylation of the E-box binding transcription fac-
tor USF and facilitate its interaction with activated
Smad2/3 to regulate PAI-1 gene expression [37]. Thus,
the RTK activated Ras-MAPK pathway converges with
the canonical TGFb pathway at chromatin in order to
regulate gene expression.
Ras-MAPK has also been shown to phosphorylate R-
Smads auxiliary to the activation regions[38,39], seques-
tering them to the cytoplasm to attenuate TGFb signaling
[39]. However, the opposite effect of activated Ras-MAPK
on Smad activity has also been reported [40-42]. A possi-
ble explanation for the contradictory observations is that
the levels of Ras activity could dictate the outcome of the
experiment [43]. In a majority of human cancers carrying
oncogenic Ras mutations, the activity rather than the
levels of Ras expression is elevated. Thus, the levels of
Ras activity translate into the levels of MAPK activity,
ultimately shaping the TGFb response via crosstalk
between R-Smads and the Ras-MAPK pathway.
The linker region between Mad Homology Domains 1
and 2 (MH1 and MH2) have been shown to be phos-
phorylated by GSK-3 and ERK1/2. Phosphorylation of
Ser204 on Smad3 via GSK-3 kinase activity results in
decreased affinity between Smad3 and CREB binding
protein, suggesting that the functional significance of
the linker region phosphorylation status is to modulate
transcription factor activity of SMAD proteins, rather
than to regulate the nucleocytoplasmic localization of
Smad proteins[44]. Consistent with this theory, the lin-
ker region phosphorylation of Smad2 and Smad3 by
ERK1/2 at positions Ser240/Ser245/Ser250 and Ser204/
Ser208/Ser215, respectively, has been shown to enhance
Smad transcriptional activity of the Type I and Type III
Collagen gene [40,45]. Additionally, Small C-terminal
Phosphatase (SCPs) in the nucleus have been shown to
dephosphorylate the linker region phosphorylation sites
in Smad2, confirming a primarily nuclear role of the lin-
ker region phosphorylation [46]. Such dephosphoryla-
tion by SCPs results in activation of Smad dependent
transcriptional regulation of exogenous luciferase repor-
ters[46]. Thus, conflicting results about the functional
consequences of linker region phosphorylation suggest
that not only is Smad2/3 transcriptional activity regu-
lated in a cell type specific manner, but also perhaps in
a single cell type discrete genes are positively or nega-
tively regulated by linker region phosphorylation in a
chromatin context dependent manner.
Taken together, the current and previously reported
data strongly suggests that different cellular responses to
TGFb stimulation in different cell types and cellular
contexts largely results from the status of MAPK activity
at the time of ligand stimulation.
Systems Features of MAPK and TGFb pathways
Even though the signaling of the TGFb and Ras-MAPK
pathways initiates upon ligand binding at the plasma
membrane, the modes of signal transmission are quite
different [47,48]. The Ras-MAPK pathway features a
cascade of sequential kinase phosphorylations/activa-
tions from RAF to ERK (Figure 1). This type of pathway
architecture can lead to significant amplification of the
original upstream receptor/ligand binding signal. The
RTKs also activate other signaling pathways such as
PLCg,P I 3 Ko rS r c .S o m eo ft h e s es i g n a l i n gp a t h w a y s
can feed into Ras-MAPK and produce positive feedback
loops. There are also multiple well characterized nega-
tive feedback loops in the Ras-MAPK pathway that
cause desensitization or dampening of the signal [49].
The presence of these feedback loops have been shown
to produce switch-like (i.e. bistable) responses to recep-
tor activation, allowing for a tight threshold of cellular
response during development [50,51].
Unlike the Ras-MAPK pathway, the TGFb signal relay
system is relatively short. There are no apparent signal
amplification steps in the signaling cascade subsequent
to the receptor phosphorylation of R-Smads. The con-
stant shuttling of Smads in and out of the nucleus
allows the Smads to constantly monitor receptor activity
[48]. This type of arrangement results in a more linear
response to ligand binding. However, a more recent
study reveals that TGFb depletion during signaling is
important to produce threshold-like input/output
response to receptor activation [52]. Clearly, there is
also nonlinearity in the TGFb pathway.
Systems analysis of biological signaling pathways sug-
gests that signaling pathways interact with one another
and the final biological response is shaped by interaction
between pathways [51]. Since there are multiple integra-
tion points between the Ras-MAPK and TGFb path-
ways, it is not a surprise that the integration of these
two pathways produces quite complex biological out-
comes, depending on the cellular context. The challenge
is how to precisely determine the behaviors of the inter-
acting pathways and how to manipulate the end-point
biological responses in normal and cancer cells.
Lesions in the Ras-MAPK and TGFb pathways in Cancers
Colorectal and pancreatic cancers are, respectively, the
fourth and fifth causes of cancer deaths [53]. More than
one third of colorectal cancer patients develop metasta-
sis. Of these cancers, about 35% are the result of genetic
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pathway [54]. Additionally, mutations that inactivate the
key signal components, including receptors and Smads,
are frequently observed within the tumor. Loss of func-
tion mutations in TbRII have been found in a majority
of colorectal and gastric carcinomas with microsatellite
instability (MSI) [55,56]. In microsatellite stable colon
cancer cell lines, missense mutations are identified in
~15% of cases [57]. Inactivating mutations of TbRI
occurs at low frequency in pancreatic and biliary carci-
nomas [58] but relatively high in ovarian cancers with
wild type TbRII [59]. In one example of TGFb pathway
lesion, TGFbRI*6A, the TGFbRI is missing three ala-
nines from the signal sequence. TGFbRI*6A was pre-
viously associated with hereditary cancers based on
analysis of a limited numbers of cases [60,61]. Recent
work using a much larger number of case studies sug-
gests that there is no increased hereditary risk of colon
cancer associated with this mutation [62]. However, it is
still possible that TGFbRI*6A does convey increased risk
in specific patient populations or in somatic mutations
[62].
Inactivation of TGF-b signaling also occurs by dis-
abling Smad proteins. SMAD4 was originally identified
as a tumor-suppressor gene lost in pancreatic cancers
called DPC4 (deleted in pancreatic cancer 4) [63]. Sub-
sequent studies revealed that deletion of Smad4 also
occurs in 16-25% of colorectal cancer [64]. Germline
mutations of SMAD4 are associated with juvenile poly-
posis and hamartomatous polyposis [65,66]. Inactivating
mutations of Smad2 have been identified in ~6% of col-
orectal cancers while loss of function mutations of
Smad3 are rare in colorectal cancers [64,67].
Escaping the TGFb growth constraint is one of the
hallmarks of tumor cells [2]. Tumor cells explore differ-
ent mechanisms to achieve this. Despite the fact that
inactivating mutations in the canonical TGFb pathways
in colorectal and pancreatic tumors are wide spread,
cells isolated from other tumor types preserve the func-
tionality of the canonical TGFb signaling components
and achieve TGFb growth resistance by altering other
aspects of the pathways [5]. Thus, oncogenic activation
can also interdict TGFb growth inhibitory responses by
modifying the activity of downstream elements such as
cell cycle inhibitors or transcriptional cofactors of Smad
transcription factor activity.
Throughout tumor progression, the TGFb ligand
becomes highly expressed and actually promotes prolif-
eration, particularly in the case of prostate cancer [68].
This may be due to its ability to stimulate MAPK path-
ways [69]. High levels of TGFb are correlated with
increased angiogenesis, as the tumor recruits blood ves-
sels to allow for greater growth by inducing greater
TGFb dependent VEGF expression [70]. In the clinic,
patients with high levels of TGFb have decreased survi-
val, likely due to aggressive tumor progression and
metastasis [71]. In addition to over secretion of the
TGFb ligand, deregulation of the intracellular pathway
can sensitize cells to an unchanging amount of TGFb
ligand. For example, in situ cell culture RNAi knock-
down of Phosphatase and Tensin Homolog (PTEN), a
TGFbR phosphatase, resulted in the increased TGFb
dependent invasion potential of cells [72]. Recent studies
also suggest that TGFb is involved, in some cell types, in
directing metastatic cells to specific locations such as
bone [73,74]. The cellular response to TGFb in tumors
clearly plays a role in tumor metastasis, even though
there is not strong evidence that R-Smads mediate this
role.
The Ras-MAPK pathway is an important component
of many cancerous cells. The majority of cancer asso-
ciated lesions to the Ras-MAPK pathway result in con-
stitutive activation of the pathway [12]. Mutations that
have been identified are located early in the pathway
and include overexpression of RTKs, activating muta-
tions to RTKs, sustained expression of activating auto-
crine or paracrine ligands, and mutations to Ras and Raf
[2,12]. Temporally, these lesions occur early in tumori-
genesis and are sustained for the life of the cancer (Fig-
ure 2). Ras mutations have been found in 30% of all
cancers, 90% of pancreatic cancers and 50% of colon
cancers [12]. B-Raf mutations have been found in 65%
of melanomas, 45% of papillary thyroid cancers and 36%
of ovarian cancer [75-77]. In summary, a large portion
of human tumors have a constitutively active Ras-
MAPK pathway and have acquired resistance to TGFb
induced cell cycle arrest. Thus, the role of TGFb in can-
cer progression seems to be largely through lesions that
stimulate the non-cannonical signaling, and are aided by
inactivating lesions in the canonical pathway, which are
associated with cell-cycle arrest and the apoptotic
response.
Crosstalk between TGFb and Ras-MAPK Signaling
Pathways drives EMT
Crosstalk between the TGFb and Ras-MAPK pathways
appears to be required for tumor metastasis, likely
through the role of crosstalk in epithelial-mesenchymal
transition (EMT). TGFb induced EMT, which is a fun-
damental mechanism thatd r i v e sm e t a s t a s i sin vivo or
invasion in vitro,r e q u i r e sc o n s t a n tT G F b signaling to
become a stable phenotype [78,79]. The connection
between EMT and metastasis is exemplified through the
finding that fibroblast cells that undergo EMT are more
conducive to promote tumor invasion [80]. EMT is
marked by changes to the actin cytoskeleton, loss of cell
polarity, and migration/invasion [35,81]. Acting alone,
neither pathway is successful in permanently converting
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Long-term expression and cooperation of TGFb and
Ras- MAPK causes full EMT through induction of cyto-
kine feedback loops that include upregulating TGFb
autocrine signaling [78]. Recently, a new mechanism by
which TGFb induces EMT has been introduced, where
TGFb induces isoform switching of fibroblast growth
factor (FGF) receptors [80]. Prolonged treatment of
TGFb results in increased FGFR1IIIc, which is the
mesenchymal isoform, and decreased expression of the
epithelial isoforms of FGF receptors. FGF-2 but not
FGF-7 signals through FGFR1IIIc[80]. The switch in
FGF-2 receptor expression enables cells to respond to
FGF-2 to activate Ras-MAPK. Furthermore, epithelial
cells treated with both TGFb and FGF-2 undergo EMT
instead of epithelial to epithelial-myofibroblastic transi-
tion (EMyoT). Thus, the crosstalk between the Ras-
MAPK and TGFb pathways may be harnessed to pro-
mote tumor growth through EMT.
Conclusions and Future Directions
Colorectal and pancreatic cancers account for a large
portion of cancer incidence and fatalities in the United
States. Thus, they are important models for the study of
the complicated roles of Ras-MAPK and TGFb path-
ways. As more is learned about these pathways in nor-
mal and cancerous cells, it becomes increasingly clear
that crosstalk between the distinct pathway components
are important for TGFb signal interpretation in a cell
type and cell context dependent manner. Future studies
are required to address the interdependency of these
pathways, paying close attention to the connection
between the cellular context in a study, the level of con-
tribution of the Ras-MAPK pathway to the TGFb
response, and the ultimate cellular response to TGFb
ligand stimulation.
A consequence of this emerging theme of crosstalk
may be the reevaluation of cancer therapeutic strategies.
Currently, Ras and Raf have been the hot targets in the
Ras-MAPK pathway for anticancer drugs. Inhibition of
isoprenylation of Ras seemed promising. However, it
appears that the enzymes that catalyze this reaction are
somewhat promiscuous and off-target effects have lim-
ited the successful development of inhibitors of Ras.
Other Ras-MAPK components such as Raf, MEK and
ERK are also being investigated and are proving more
Figure 2 Schematic showing the transitions from healthy to metastatic cells and the corresponding changes to TGFb and MAPK
signaling.
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been approved by the FDA for treatment of renal cell
carcinoma and a handful of other drugs are in Phase I/
II/III trials that target Raf and MEK [82]. TGFb’si n v o l -
vement in promoting a metastatic phenotype in aggres-
sive cancers makes it a highly sought after pathway to
target for anticancer therapies. The obvious targets of
choice are the TGFb ligand itself, the ligand- binding
surface on TGFbRI/II and betaglycan [83]. As a result, a
humanized anti- TGFb monoclonal antibody (GC1008)
is in Phase I/II clinical trials. Additionally, soluble
TGFbRII and betaglycan recombinant receptors, which
compete for extracellular TGFb, as well as inhibitors
TGFbRI kinase activity have shown encouraging anti-
metastatic results [84]. As might be the case for many
kinase inhibitors, long term administration of a single
agent may select for more aggressive drug resistant
tumor variants, as has been demonstrated for
LY2109761, a TbRI/TbRII kinase inhibitor in a mouse
skin model [85]. Considering the synergistic effects of
TGFb and MAPK pathways in tumorigenesis it is logical
to try a combinatorial approach in cancer treatments,
where simultaneous partial inhibition of the Ras-MAPK
and TGFb pathways, yields synergistic inhibition of
TGFb ligand induced metatstasis, while having minimal
impact on other aspects of TGFb and Ras-MAPK
biology.
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